BR112014002675A2 - "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição" - Google Patents
"quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"Info
- Publication number
- BR112014002675A2 BR112014002675A2 BR112014002675A BR112014002675A BR112014002675A2 BR 112014002675 A2 BR112014002675 A2 BR 112014002675A2 BR 112014002675 A BR112014002675 A BR 112014002675A BR 112014002675 A BR112014002675 A BR 112014002675A BR 112014002675 A2 BR112014002675 A2 BR 112014002675A2
- Authority
- BR
- Brazil
- Prior art keywords
- serine
- kinase inhibitors
- quinazoline
- composition
- threonine kinase
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 title abstract 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 title abstract 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515165P | 2011-08-04 | 2011-08-04 | |
| PCT/US2012/049551 WO2013020062A1 (en) | 2011-08-04 | 2012-08-03 | Quinazoline compounds as serine/threonine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014002675A2 true BR112014002675A2 (pt) | 2017-02-21 |
Family
ID=47003195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014002675A BR112014002675A2 (pt) | 2011-08-04 | 2012-08-03 | "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição" |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9187462B2 (enExample) |
| EP (1) | EP2739618B1 (enExample) |
| JP (1) | JP6097289B2 (enExample) |
| KR (1) | KR101979042B1 (enExample) |
| CN (1) | CN103958502B (enExample) |
| BR (1) | BR112014002675A2 (enExample) |
| CA (1) | CA2844058A1 (enExample) |
| ES (1) | ES2552989T3 (enExample) |
| MX (1) | MX340756B (enExample) |
| RU (1) | RU2014108140A (enExample) |
| WO (1) | WO2013020062A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2828478C (en) | 2011-02-28 | 2019-12-31 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| WO2013020062A1 (en) | 2011-08-04 | 2013-02-07 | Array Biopharma Inc. | Quinazoline compounds as serine/threonine kinase inhibitors |
| AU2013225737B2 (en) | 2012-03-01 | 2018-03-01 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| BR112015004548A2 (pt) * | 2012-08-27 | 2017-08-08 | Array Biopharma Inc | inibidores de serina/treonina para tratamento de doenças hiperproliferativas |
| MX2015004615A (es) | 2012-10-16 | 2015-07-17 | Hoffmann La Roche | Inhibidores de serina/treonina cinasa. |
| CN103254142B (zh) * | 2013-04-26 | 2015-10-28 | 浙江工业大学 | 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用 |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| JP6449293B2 (ja) | 2013-12-06 | 2019-01-09 | ジェネンテック， インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| WO2015103133A1 (en) * | 2013-12-30 | 2015-07-09 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| EP3089980B1 (en) * | 2013-12-30 | 2018-01-31 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors |
| CA2946538A1 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| WO2017180581A1 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| EP3679159A1 (en) | 2017-09-08 | 2020-07-15 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| WO2019158579A1 (en) | 2018-02-13 | 2019-08-22 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| WO2019213403A1 (en) | 2018-05-02 | 2019-11-07 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| AU2019291935A1 (en) | 2018-06-29 | 2021-02-04 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| CN113227089B (zh) | 2018-10-31 | 2024-07-05 | 吉利德科学公司 | 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CA3154247A1 (en) * | 2019-10-25 | 2021-04-29 | Mitchell H. KEYLOR | N-(heteroaryl) quinazolin-2-amine derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| CN115448864B (zh) * | 2022-08-26 | 2023-12-22 | 上海方予健康医药科技有限公司 | 3-氟-3-（1-羟乙基）吡咯烷-1-羧酸叔丁酯的制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU693114B2 (en) | 1993-10-01 | 1998-06-25 | Novartis Ag | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
| AU693475B2 (en) | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| BR9713863A (pt) | 1996-12-05 | 2000-03-14 | Amgen Inc | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| CA2398274C (en) | 2000-02-25 | 2009-09-22 | F. Hoffmann-La Roche Ag | Adenosine receptor modulators |
| EP1510222A3 (en) | 2000-04-26 | 2007-05-23 | Eisai R&D Management Co., Ltd. | Medicinal compositions promoting bowel movement |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| CA2485166A1 (en) | 2002-05-21 | 2003-12-04 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds |
| US7208498B2 (en) | 2002-07-15 | 2007-04-24 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| WO2005080373A1 (en) * | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
| ATE485824T1 (de) | 2004-04-13 | 2010-11-15 | Icagen Inc | Polycyclische pyrimidine als kaliumionenkanal- modulatoren |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| CA2578122A1 (en) | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| JP2008536950A (ja) | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのｃｂ１拮抗薬 |
| US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| US7807672B2 (en) | 2006-02-16 | 2010-10-05 | Schering Corporation | Compounds that are ERK inhibitors |
| US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
| DE102006035202A1 (de) | 2006-07-29 | 2008-01-31 | Lanxess Deutschland Gmbh | Konservierungsmittel auf Basis von Carbonsäureanhydriden |
| EP2057141B1 (en) | 2006-08-23 | 2011-10-26 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| AU2007336933A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections |
| WO2009032861A1 (en) | 2007-09-04 | 2009-03-12 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| KR20100088150A (ko) | 2007-11-06 | 2010-08-06 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 살진균성 복소환식 아민 |
| US20090246198A1 (en) * | 2008-03-31 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| MX2010014572A (es) | 2008-06-27 | 2011-03-24 | Novartis Ag | Compuestos organicos. |
| TWI458721B (zh) | 2008-06-27 | 2014-11-01 | Celgene Avilomics Res Inc | 雜芳基化合物及其用途 |
| ES2548882T3 (es) | 2008-12-08 | 2015-10-21 | Arena Pharmaceuticals, Inc. | Moduladores del receptor de prostaciclina (PGl2) útiles para el tratamiento de trastornos relacionados con los mismos |
| CA2828478C (en) | 2011-02-28 | 2019-12-31 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| WO2013020062A1 (en) | 2011-08-04 | 2013-02-07 | Array Biopharma Inc. | Quinazoline compounds as serine/threonine kinase inhibitors |
| AU2013225737B2 (en) | 2012-03-01 | 2018-03-01 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| BR112015004548A2 (pt) | 2012-08-27 | 2017-08-08 | Array Biopharma Inc | inibidores de serina/treonina para tratamento de doenças hiperproliferativas |
-
2012
- 2012-08-03 WO PCT/US2012/049551 patent/WO2013020062A1/en not_active Ceased
- 2012-08-03 MX MX2014001389A patent/MX340756B/es active IP Right Grant
- 2012-08-03 KR KR1020147005731A patent/KR101979042B1/ko not_active Expired - Fee Related
- 2012-08-03 EP EP12769775.3A patent/EP2739618B1/en active Active
- 2012-08-03 CA CA2844058A patent/CA2844058A1/en not_active Abandoned
- 2012-08-03 RU RU2014108140/04A patent/RU2014108140A/ru not_active Application Discontinuation
- 2012-08-03 BR BR112014002675A patent/BR112014002675A2/pt not_active IP Right Cessation
- 2012-08-03 US US14/237,143 patent/US9187462B2/en active Active
- 2012-08-03 ES ES12769775.3T patent/ES2552989T3/es active Active
- 2012-08-03 CN CN201280049268.3A patent/CN103958502B/zh active Active
- 2012-08-03 JP JP2014524111A patent/JP6097289B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014108140A (ru) | 2015-09-10 |
| WO2013020062A1 (en) | 2013-02-07 |
| KR101979042B1 (ko) | 2019-05-15 |
| US9187462B2 (en) | 2015-11-17 |
| HK1199021A1 (zh) | 2015-06-19 |
| KR20140062057A (ko) | 2014-05-22 |
| JP6097289B2 (ja) | 2017-03-15 |
| MX2014001389A (es) | 2014-11-13 |
| MX340756B (es) | 2016-07-25 |
| CN103958502B (zh) | 2016-02-10 |
| US20150087664A1 (en) | 2015-03-26 |
| CN103958502A (zh) | 2014-07-30 |
| CA2844058A1 (en) | 2013-02-07 |
| HK1199248A1 (zh) | 2015-06-26 |
| EP2739618B1 (en) | 2015-09-16 |
| ES2552989T3 (es) | 2015-12-03 |
| JP2014521696A (ja) | 2014-08-28 |
| EP2739618A1 (en) | 2014-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014002675A2 (pt) | "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição" | |
| BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
| HK1210174A1 (en) | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases | |
| BR112013021896A2 (pt) | inibidores de serina/treonina cinase | |
| BR112013025387A2 (pt) | análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl | |
| BR112014022000A8 (pt) | compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende | |
| BR112015020350A2 (pt) | derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd | |
| BR112014004560A2 (pt) | compostos e composições como inibidores de c-kit quinase | |
| EA201391230A1 (ru) | Соединения и композиции в качестве ингибиторов trk | |
| BR112014030812A2 (pt) | "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr" | |
| BR112013029640A2 (pt) | derivados de piridina e pirazina | |
| CR20130487A (es) | 1,3-oxazinas como inhibidores de BACE1 y/o BACE2 | |
| BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
| PH12014500373A1 (en) | Amino quinazolines as kinase inhibitors | |
| BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
| MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
| BR112012010186B8 (pt) | derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos | |
| BR112014004504A2 (pt) | "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" | |
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| BR112016014412A2 (pt) | Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo | |
| MX2013008212A (es) | Derivados de 7-azaindol. | |
| BR112014004319A2 (pt) | compostos e composições como inibidores de c-kit cinase | |
| BR112014003963A2 (pt) | compostos e composições como inibidores de quinase c-kit | |
| BR112013031405A2 (pt) | piridopirazinas substituídas como novos inibidores de syk | |
| PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2631 DE 08-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |